For virologically suppressed adult patients with HIV-1. See Full Indication.

JULUCA | Lipid and Fracture Data and a DEXA Substudy

Neutral Effect on Lipids

In pooled data from SWORD 1 & 2, a secondary endpoint evaluated lipids at 48 weeks1

Neutral Effect on Lipids
Neutral Effect on Lipids
  • No discernible pattern of changes from baseline in mean serum concentrations of lipids at Week 1482

HDL=high-density lipoprotein; LDL=low-density lipoprotein; ART=antiretroviral therapy.

Fractures Reported in SWORD 1 & 2 (Pooled Data) at 48 Weeks

Fractures Reported in SWORD 1 & 2 (Pooled Data) at 48 Weeks
Fractures Reported in SWORD 1 & 2 (Pooled Data) at 48 Weeks

A DEXA Substudy of SWORD 1 & 2 Evaluating Bone Mineral Density1,3

A DEXA substudy evaluated the change in BMD at 48 weeks following a switch from an ART regimen containing TDF to JULUCA once daily compared with continued therapy with the TDF-containing regimen

102 patients were included; median age was 43 years for JULUCA, 46 years for continuing ART; percentage of females was 51% for JULUCA, 53% for continuing ART

Primary endpoint was percentage change from baseline at Week 48 in total hip BMD; percentage change in lumbar spine BMD was a secondary endpoint

DEXA=dual-energy X-ray absorptiometry; BMD=bone mineral density.

Change in hip BMD at Week 481

(Primary endpoint)

Change in lumbar spine BMD at Week 481

(Secondary endpoint)

Change in BMD
Change in BMD

CI=confidence interval.

  • BMD declines of ≥5% at the lumbar spine were experienced by 2% of patients receiving JULUCA and 5% of patients who continued their TDF-containing regimen
  • In subjects who received JULUCA from study start and were continuing JULUCA at Week 148, mean BMD increases from baseline were 0.98% (total hip) and 0.53% (lumbar spine)
  • The long-term clinical significance of these BMD changes is not known


  1. Data on file, ViiV Healthcare.
  2. Aboud M, Orkin C, Podzamczer D, et al. Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies. Lancet HIV. 2019, Epub ahead of print.
  3. McComsey GA, Lupo S, Parks D. Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health. AIDS. 2018;32(4):477-485. doi: 10.1097/QAD.0000000000001725.

You may also be interested in

Trial Design


Read more »


Read more »
Adverse Reactions


Read more »